Increasing Access to HCT for Sickle Cell Disease: Connecting Transplant Centers and Sickle Cell Programs

Includes a Live Web Event on 09/28/2022 at 1:00 PM (CDT)

During this interactive roundtable-style webinar, our expert HCT and SCD panelists will discuss some of the latest research and outcomes in HCT for SCD, as well as share models for outreach and engagement between transplant centers and SCD programs. Panelists will further explore the role of HCT in the treatment of SCD and how to ensure access to HCT for these patients as a matter of health equity, including through patient programs like the Sickle Cell Warrior Program and HLA Today. This webinar will be relevant for both transplant centers and community hematologists/oncologists and SCD program providers who refer out for transplant and cellular therapies, discussing the role that all practitioners can play in improving access to HCT. 

Accreditation Statement: In support of improving patient care, this activity has been planned and implemented by The France Foundation, National Marrow Donor Program, and American Society for Transplantation and Cellular Therapy (ASTCT). The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PLANNING COMMITTEE MEMBERS

FACULTY

Stephen Spellman
Vice President, Research 
Senior Scientific Director, CIBMTR-NMDP/Be The Match

Heather Stefanski, MD, PhD
Vice President, Medical Services
NMDP/Be The Match

Elizabeth Stenger, MD
Pediatric Hematologist/Oncologist, Bone Marrow Transplant Physician
Children’s Healthcare of Atlanta

Ashish Gupta, MD, MPH 
University of Minnesota

Samuel Anim, MD
Pediatric Hematologist/Oncologist
Sanford Roger Maris Cancer Center, Fargo, ND

ADDITIONAL PLANNERS

Alejandro Marinos Velarde, MD
MD Anderson Cancer Center

Samantha Watters, MPH
Research and Education Lead, NMDP/Be The Match

Kelly Wilson, MSN, RN
Research/Education Specialist, NMDP/Be The Match

Karla Dawson, MPH
Health Equity Analyst, NMDP/Be The Match

Kyra Newman, MSW
ASTCT Education Manager

Jas Chahal, PhD
Manager of Outcomes and Accreditation
The France Foundation

Heather Tarbox, MPH
Director of Education and Compliance, The France Foundation

PROGRAM OVERVIEW
This webinar will focus on recent research in the use of hematopoietic cell transplant (HCT) for the treatment of sickle cell disease (SCD), convening a panel of experts to discuss ways to improve access for SCD patients who could benefit from HCT. Many patients and providers alike are unfamiliar with HCT as a potential curative option for SCD patients. Demystifying transplant among SCD providers and encouraging strong relationships between transplant centers and community providers treating SCD patients can help open up HCT as an option for these patients. Disparities in health care among racial and ethnic groups are well established, and the lack of discussion of HCT among SCD patients and providers presents another example of differential access to care. Several transplant programs who routinely transplant SCD patients are working to make stronger connections with local community SCD treatment programs to help overcome these barriers to care and encourage discussion about HCT’s place in the treatment of SCD. 

During this interactive roundtable-style webinar, our expert HCT and SCD panelists will discuss some of the latest research and outcomes in HCT for SCD, as well as share models for outreach and engagement between transplant centers and SCD programs. Panelists will further explore the role of HCT in the treatment of SCD and how to ensure access to HCT for these patients as a matter of health equity, including through patient programs like the Sickle Cell Warrior Program and HLA Today. This webinar will be relevant for both transplant centers and community hematologists/oncologists and SCD program providers who refer out for transplant and cellular therapies, discussing the role that all practitioners can play in improving access to HCT. 

LEARNING OBJECTIVES
Upon completion of the activity, participants should be able to:
Identify recent trends in access to and outcomes of HCT for SCD
Discuss models for outreach and engagement to improve shared, coordinated care between transplant centers treating SCD patients and community hematology/oncology or SCD programs
Describe the role of HCT in the treatment of SCD 
Explain how transplant centers and hematology/oncology or SCD providers can work together to improve health equity and access to HCT
Use patient resources for SCD through the Sickle Cell Warrior Program and HLA Today

TARGET AUDIENCE
This activity is intended for physicians and other members of the health care team who care for patients with sickle cell disease.

INSTRUCTIONS FOR PARTICIPATION AND REQUESTING CREDIT
There are no fees for participating and receiving credit for this activity. Successful completion is achieved by reviewing the CME information, completing the activity, and evaluation form. Your CME certificate will be available for download.

ACCREDITED PROVIDER 
This activity is jointly provided by The France Foundation, National Marrow Donor Program, and American Society for Transplantation and Cellular Therapy (ASTCT). In support of improving patient care, this activity has been planned and implemented by The France Foundation, National Marrow Donor Program, and American Society for Transplantation and Cellular Therapy. The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CREDIT DESIGNATION
Physician Credit Designation

The France Foundation designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

All other healthcare professionals completing this course will be issued a statement of participation.

DISCLOSURE POLICY
In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF), the National Marrow Donor Program (NMDP), and the American Society for Transplantation and Cellular Therapy (ASTCT) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF, NMDP, and ASTCT resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF NMDP, and ASTCT seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF NMDP, and ASTCT are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Planning committee members, faculty, reviewers, and activity staff have disclosed the following relevant financial relationships. All relevant financial relationships listed have been mitigated.

Name  of Individual

Individual’s Role in Activity

Name of Commercial Entity

Nature of Relationship(s)

Mechanism(s) implemented to resolve conflict of interest

Alejandro Marinos Velarde, MD

Planner

No relevant financial disclosures

NA

NA

Ashish Gupta, MD, MPH

Planner and Faculty

No relevant financial disclosures

NA

NA

Elizabeth Stenger, MD

 

Planner and Faculty

No relevant financial disclosures

NA

NA

Heather Stefanski, MD, PhD

Planner and Faculty

No relevant financial disclosures

NA

NA

Heather Tarbox, MPH

TFF Staff

No relevant financial disclosures

NA

NA

Jas Chahal, PhD

TFF Staff

No relevant financial disclosures

NA

NA

Karla Dawson, MPH

 

NMDP Staff

No relevant financial disclosures

NA

NA

Kelly Wilson, MSN, RN

 

NMDP Staff

No relevant financial disclosures

NA

NA

Kyra Newman

ASTCT Staff

No relevant financial disclosures

NA

NA

Samantha Watters, MPH

NMDP Staff

No relevant financial disclosures

NA

NA

Samuel Anim, MD

 

Planner and Faculty

No relevant financial disclosures

NA

NA

Stephen Spellman

Planner and Faculty

No relevant financial disclosures

NA

NA

DISCLOSURE OF UNLABELED USE
TFF, NMDP, and ASTCT require CE faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF, NMDP, and ASTCT do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information. 

DISCLAIMER 
TFF, NMDP, and ASTCT present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. TFF, NMDP, and ASTCT assume no liability for the information herein.

CONTACT INFORMATION
If you have questions about this CE activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Key:

Complete
Failed
Available
Locked
Live Webinar
09/28/2022 at 1:00 PM (CDT)   |  60 minutes
09/28/2022 at 1:00 PM (CDT)   |  60 minutes